Introduction {#sec1-1}
============

It has been reported that up to 60-90% of patients with bone metastases would experience severe bone pain in the terminal stages of their disease.\[[@ref1]\] For prevention of skeletal-related events majority of patients now receive infusion of bisphosphonates. The new generation of bisphosphonates exhibits highly potent inhibitory activity on osteoclasts. These compounds are also known to provide pain relief. A previous randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma had shown an increase in pain and analgesic scores more in patients who received placebo than in patients who received zoledronic acid. Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated, but the 8-mg dose was associated with renal function deterioration.\[[@ref2]\]

Radionuclide therapy is widely used as an effective modality in the management of bone pain. Bone seeking radiopharmaceuticals like Samarium-153 EDTMP, Sr-89, etc., have affinity for skeletal tissue and when administered intravenously they concentrate in areas of increased bone turnover,\[[@ref3]\] localizing in active bone and mainly at metastatic lesions, allowing site-directed radiotherapy.\[[@ref4]\] Combined treatment with both pharmaceuticals, i.e., Zoledronic acid and radiopharmaceutical may improve palliative care and enhance overall efficacy of bone pain palliation.\[[@ref5]--[@ref8]\]

Some authors have demonstrated that the combination of both treatments is globally more effective as compared to either one in isolation.\[[@ref5]--[@ref7]\] However, there are conflicting reports to suggest that bisphosphonates could inhibit the uptake of radiolabeled phosphonates in bone metastases.\[[@ref9]--[@ref14]\] To this effect in one specific study analyses of the cumulative activity of radiotracer excreted in the urine of hormone-refractory prostate cancer patients who were treated with Sm-153 EDTMP were carried out. The patients were first treated with Sm-153 EDTMP followed by Zoledronic acid after 48 hours. The authors reported no statistically significant difference in radioactivity between the two urine samples and concluded that Zoledronic acid does not influence Sm-153 EDTMP uptake by the osteoblastic bone lesions. Nevertheless, they reported musculoskeletal side effects of Zoledronic acid which include bone pain (55%), myalgia (23%0, arthralgia (21%), back pain (15%), and limb pain (14%).\[[@ref7][@ref15]\] Radionuclide therapy may also lead to transient flare effect on bone pain.\[[@ref15]\] The purpose of our study was to seek further clarification about the combined therapy, especially for determining the exact temporal sequence of bisphosphonates administration in patients receiving combined therapy in order to achieve optimal efficacy of bone pain palliation by comparing different regimes of Zoledronic acid administration in combined treatment of widespread bone metastases with Samarium-153 oxabifore (Oxa-bis ethylennitrilo-tetramethyl phosphonic acid-ETMP).

Materials and Methods {#sec1-2}
=====================

Patients {#sec2-1}
--------

Ninety-three patients with widespread bone metastases who received combined treatment of Sm-153 oxabifore and Zoledronic acid were divided into three groups according to the timing of Zoledronic acid (Zometa) administration.

Group I consisted of 39 patients (32 females and 7 males, aged 35-71, mean age 54,4 + 8.0) with multiple skeletal metastases from prostatic (*N* = 7) and breast carcinoma (*N* = 32) received Zoledronic acid 7 and more days prior to Sm-153 oxabifore treatment. Group II consisted of 32 patients (21 females and 11 males, age 38-72, (mean age 57.1 ± 9.7), all with multiple skeletal metastases from prostate (*N* = 10), breast (*N* = 20), and kidney (*N* = 2) cancers. They received Zoledronic acid 48-72 hours prior to Sm-153 oxabifore treatment. Group III consisted of 22 patients (20 females and 2 males, age 29-66, mean age 53 ± 10.3) with bone metastases from breast (*N* = 20), prostate (*N* = 1), and gastric (*N* = 1) carcinomas. In this group, patients received Zoledronic acid 7 days after Sm-153 oxabifore treatment \[[Table 1](#T1){ref-type="table"}\].

###### 

Patient population and initial status of pain score before Sm-153 Oxabifore administration

![](WJNM-12-14-g001)

Pain assessment was based on visual analog scale (VAS), with 0 representing no pain and 10 representing intolerable pain. Initially there was no significant difference in mean objective pain score according to VAS system between groups of patients at the time of Sm-153 oxabifore administration.

Computed tomography (CT) and magnetic resonance imaging (MRI) examinations were performed before treatment in all patients to exclude cord compression and vertebral fractures.

Sm-153 oxabifore therapy {#sec2-2}
------------------------

Inclusion criteria in brief for therapy were (1) intense uptake around painful metastases on recent (3-4 weeks before treatment) Tc-99m methylene diphosphonates (MDP) whole body (WB) bone scan, (2) hemoglobin \>90 g/L, (3) white blood cell count \>4 × 10^9^/L, and (4) platelet count of \>100 × 10^9^/L.

Prior to the administration of the radiopharmaceutical the patients received information both orally and in written pamphlet about the procedure, including an explanation of the therapeutic procedure and radiation protection guidelines; estimated time when to expect possible pain relief, a warning that transient flare effect of pain may occur, and a note on general radiation protection guidelines. Sm-153 oxabifore was administered to all patients at the standard bone palliation dose of 37 MBq/kg body weight. Whole body post-treatment scans were obtained within 3-6 hours after Sm-153 oxabifore administration in all patients.

All patients received Zoledronic acid before and after treatment as per the protocol in standard dosage, 4 mg every 28 days under control of serum urea and creatinine levels. To calculate creatinine clearance we used Cockroft and Gault formula, where creatinine clearance in ml/min= \|(140 - age) × weight (kg) × C/plasma creatinine × 0:814)\| in which C = 1 if male, C = 0.85 if female; plasma creatinine in μmol/l).

Since Zoledronic acid may lead to renal toxicity we excluded from this study patients with creatinine clearance \<50 ml/min because they would have needed to change into other bisphosphonate instead of taking Zoledronic acid. Types and doses of prescribed analgesics as well as VASs were recorded.

Statistical analysis {#sec2-3}
--------------------

The acquired results were expressed as the mean + SEM for each index. Comparison of data among various groups was performed with Student\'s unpaired *t*-test. A *P* \< 0.05 was considered statistically significant.

Results {#sec1-3}
=======

In patients belonging to Group I pain relief started around 10.4 ± 3.1 days (min 5d, max-15 d) days after Sm-153 oxabifore administration. Transient flare effect of pain was registering twice: First after Zoledronic acid administration and later after Sm-153 treatment \[[Figure 1](#F1){ref-type="fig"}\].

![Response to therapy in the three different groups with regard to pain relief. In group I pain relief occurred around 10.4+3.1 (Range=5-15) days after Sm-153 oxabifore treatment. Transient flare effect of pain was registering twice: After Zoledronic acid administration (Red segment) and after Sm-153 treatment (Yellow segment). In group II pain relief occurred earlier by 3.1+1.1 (Range=1-5) days after combined therapy. In most of the patients in this group post-therapy flare effect of pain occurred mostly following Zoledronic acid administration and not after Sm-153 oxabifore treatment. In group III pain relief started after a prolonged time, of about 22 +5.1 (Range=15-35) days following combined treatment. Transient flare effect on pain could be noticed in this group of patients twice; once after Sm-153 oxabifore administration and again after administration of Zoledronic acid](WJNM-12-14-g002){#F1}

In Group II pain relief occurred earlier by 3.1 ± 1.1 days (min-1d, max-5d) after combined therapy. In most of the patients in this group, post-therapy flare effect of pain occurred mostly following Zoledronic acid administration and not after Sm-153 oxabifore treatment.

Patients belonging to Group III took a much longer time to feel the benefit of therapy. In this group pain relief occurred after a much longer period of about 22 ± 5.1 days (min-15d, max-35d) following combined treatment. Transient flare effect on pain could be noticed in this group of patients twice; once after Sm-153 oxabifore administration and again after administration of Zoledronic acid.

The comparison of VAS among all groups of patients after treatment revealed statistically significant differences in pain score between patients belonging to Group II and rest of the patients belonging to Groups I and III \[[Figure 2](#F2){ref-type="fig"}\].

![Comparison of VASs in all three groups of patients after treatment revealed statistically significant differences in pain score between patients belonging to group II and rest of the patients belonging to groups I and III](WJNM-12-14-g003){#F2}

According to the visual analyses of Tc-99m MDP bone scans and Sm-153 oxabifore post treatment scans, no significant difference could be noticed in all groups of patients between the diagnostic Tc-99m MDP and post therapy Sm-153 Oxabifore scans \[[Figure 3](#F3){ref-type="fig"}\].

![Examples of Paired THERONOSTIC Images of Tc-99m MDP pre-therapy diagnostic whole body bone scans (Column-A) and post-therapy Sm-153 Zoledronic Acid whole body scans (Column B) in patients belonging to Groups I (top panel), II (middle panel) and III (bottom panel). Visual examination of scans did not reveal ny significant difference between the diagnostic and post therapy scans in all three groups](WJNM-12-14-g004){#F3}

Discussion {#sec1-4}
==========

Several studies in the past have reported the comparable efficacy of radionuclide therapy alone *vis a vis* combined therapy with bisphosphonates using a number of radio-conjugates including Sr-89 Chloride, Sm-153 EDTMP and Re-186 HEDP.\[[@ref5][@ref6][@ref13][@ref15]\] All studies have demonstrated better efficacy of combined therapy (Radionuclide + Bisphosphonates) compared to radionuclide therapy alone. Combined therapies resulted in quicker response to pain palliation, better pain relief, and better quality of life in all studies. All studies have reported that combined therapy is feasible and safe. All studies reported comparable toxicity with regard to hematological toxicity.

However, none of the studies, to the best of our knowledge has addressed the timing of bisphosphonates administration in relation to the radionuclide therapy; whether to give bisphosphonates before or after radionuclide administration; if so how long before or after.

In the current study we observed significant reduction of the pain score across all groups. But the best results with regard to onset of response and degree of pain relief were seen in the group of patients who received Zometa 2-3 days prior to Sm-153 oxabifore administration.

Conclusion {#sec1-5}
==========

Based on our results we concluded that (1) combined therapy with beta emitting radionuclides and bisphosphonates (Zoledronic acid) is better than radionuclide therapy alone; (2) bisphosphonates do not influence skeletal uptake of Sm-153 oxabifore and (3) administration of Zoledronic acid 48-72 hours prior to Sm-153 oxabifore treatment gives the best results with regard to faster onset of response, higher degree of pain relief and better quality of life. However, it may be noted that our study was conducted in a smaller group of patients. For a better understanding of the pathophysiology of combined therapy, a more comprehensive study may be required in a larger group of patients in the future.
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